Psychedelic Medicine

Association

Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation

Excerpts from the publication

Recent studies have demonstrated the promise of psilocybin therapies in creating positive changes for those with poor mental health across multiple diagnostic categories, including major depressive disorder (MDD), end-of-life anxiety, and obsessive-compulsive disorder (OCD). While there may be a large population that is eligible to participate in psilocybin therapy based on psychiatric diagnosis and medical clearance, little attention has been given to intrapersonal and interpersonal factors that might influence patient’s readiness (i.e., eligibility and capacity) for psychedelic interventions. This paper proposes that readiness assessment includes both intrapersonal and interpersonal factors in order to improve safety, patient care, and treatment outcomes. While at the present time a reliable and valid instrument has not been developed, we propose that three specific areas of focus – patient presentation, therapeutic alliance, and patient safety – may be used to establish a patient’s readiness for psilocybin therapy, thus increasing therapy optimization and personalization.

Read more

Case report: Prolonged amelioration of mild red-green color vision deficiency following psilocybin mushroom use

The potential of ketamine for posttraumatic stress disorder: a review of clinical evidence

Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants

Understanding the variability in ketamine’s efficacy in managing treatment-resistant depression

Psychedelics in developmental stuttering to modulate brain functioning: a new therapeutic perspective?

Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin